TABLE 2.
Descriptive characteristics by vaccination status, VEBIS‐EHR study, October to November 2023.
| Variable | Not vaccinated | Vaccinated | |||
|---|---|---|---|---|---|
| Count | % of cohort total | Count | % of cohort total | ||
| Sex | Female | 9,712,250 | 55% | 2,378,148 | 53% |
| Male | 7,901,263 | 45% | 2,118,470 | 47% | |
| Missing | 22 | 0% | < 5 | — | |
| Comorbidities | High‐risk comorbidities/immunocompromising | 479,967 | 3% | 393,205 | 9% |
| Medium‐risk comorbidities/non‐immunocompromising | 6,398,375 | 36% | 2,261,177 | 50% | |
| No comorbidity | 10,708,009 | 61% | 1,829,422 | 41% | |
| Missing | 27,184 | 0% | 12,815 | 0% | |
| Number of previous vaccine boosters | 0 | 1,745,023 | 10% | 16,981 | 0% |
| 1 | 8,386,032 | 48% | 226,135 | 5% | |
| 2 | 6,301,163 | 36% | 2,837,619 | 63% | |
| 3 | 1,177,481 | 7% | 1,413,806 | 31% | |
| 4 | 2472 | 0% | 16 | 0% | |
| 5 | 39 | 0% | — | 0% | |
| Missing | 1325 | 0% | 2062 | 0% | |
| Country of birth | Native | 13,243,192 | 75% | 1,397,411 | 31% |
| Non‐native | 508,094 | 3% | 39,082 | 1% | |
| Missing | 3,862,249 | 22% | 3,060,126 | 68% | |
| Nationality | National | 1,726,175 | 10% | 1,121,558 | 25% |
| Nonnational | 330,884 | 2% | 57,029 | 1% | |
| Missing | 15,556,476 | 88% | 3,318,032 | 74% | |
| Vaccine product | Pfizer (monovalent) | — | — | 61,332 | 1% |
| Moderna (monovalent) | — | — | 60 | 0% | |
| Pfizer (bivalent original/BA.1) | — | — | 4006 | 0% | |
| Moderna (bivalent original/BA.1) | — | — | 10 | 0% | |
| Pfizer (bivalent original/BA.4/BA.5) | — | — | 10,914 | 0% | |
| Moderna (bivalent original/BA.4/BA.5) | — | — | 116 | 0% | |
| Pfizer (XBB.1.5) | — | — | 4,370,556 | 97% | |
| Moderna (XBB.1.5) | — | — | 49,624 | 1% | |
| Novavax | — | — | — | 0% | |
| Other (all other types, including AZ) | — | — | < 5 | — | |
| Missing | — | — | — | 0% | |